Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Medical guidelines

Vol. 151 No. 3738 (2021)

Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer

  • Susanna Stoll
  • Sheila Unger
  • Silvia Azzarello-Burri
  • Pierre Chappuis
  • Rossella Graffeo
  • Gabriella Pichert
  • Benno Röthlisberger
  • Francois Taban
  • Salome Riniker
DOI
https://doi.org/10.4414/SMW.2021.w30038
Cite this as:
Swiss Med Wkly. 2021;151:w30038
Published
13.09.2021

Summary

This paper presents the Swiss guideline for genetic counselling and testing of individuals with an increased probability for carrying mutations in high risk cancer predisposition genes, particularly BRCA1 and BRCA2. It aims to help providers of genetic counselling to identify valuable candidates for testing and serves as a basis for reimbursement claims to Swiss insurance companies.

References

  1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: Breast, Ovarian, and Pancreatic Version 2.2021. Available from: https://www.nccn.org
  2. National Institute for Health and Clinical Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical guideline (CG164), last update 20 November 2019. Available from: https://www.nice.org.uk
  3. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung. Available from: https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/1995/4964_4964_4964/20210101/de/pdf-a/fedlex-data-admin-ch-eli-cc-1995-4964_4964_4964-20210101-de-pdf-a.pdf Ordonnance du DFI sur les prestations dans l’assurance obligatoire des soins en cas de maladie. Available from: https://www.fedlex.admin.ch/eli/cc/1995/4964_4964_4964/fr Ordinanza del DFI sulle prestazioni dell’assicurazione obbligatoria delle cure medico-sanitarie. Available from: https://www.fedlex.admin.ch/eli/cc/1995/4964_4964_4964/it
  4. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020 Jun;38(18):2080–106. https://doi.org/10.1200/JCO.20.00299
  5. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al.; US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Aug;322(7):652–65. https://doi.org/10.1001/jama.2019.10987
  6. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 2000 Feb;283(5):617–24. https://doi.org/10.1001/jama.283.5.617
  7. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Dec;379(26):2495–505. https://doi.org/10.1056/NEJMoa1810858
  8. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al.; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274–84. https://doi.org/10.1016/S1470-2045(17)30469-2
  9. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug;377(6):523–33. https://doi.org/10.1056/NEJMoa1706450
  10. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 Aug;379(8):753–63. https://doi.org/10.1056/NEJMoa1802905
  11. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul;381(4):317–27. https://doi.org/10.1056/NEJMoa1903387
  12. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al.; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec;383(24):2345–57. https://doi.org/10.1056/NEJMoa2022485
  13. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000 Nov;83(10):1301–8. https://doi.org/10.1054/bjoc.2000.1407
  14. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019 Jul;11:543–61. https://doi.org/10.2147/CLEP.S206949
  15. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al.; BRCA1 and BRCA2 Cohort Consortium. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017 Jun;317(23):2402–16. https://doi.org/10.1001/jama.2017.7112
  16. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016 Apr;2(4):482–90. https://doi.org/10.1001/jamaoncol.2015.5495
  17. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014 Jul;32(19):2001–9. https://doi.org/10.1200/JCO.2013.53.6607
  18. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015 Nov;33(31):3660–7. https://doi.org/10.1200/JCO.2015.63.0996
  19. Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017 May;123(10):1721–30. https://doi.org/10.1002/cncr.30498
  20. Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Sep;318(9):825–35. https://doi.org/10.1001/jama.2017.11137
  21. Sun L, Brentnall A, Patel S, Buist DS, Bowles EJ, Evans DG, et al. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol. 2019 Oct;5(12):1718–30. https://doi.org/10.1001/jamaoncol.2019.3323
  22. Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007 Jun;297(23):2587–95. https://doi.org/10.1001/jama.297.23.2587
  23. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999 Apr;64(4):963–70. https://doi.org/10.1086/302320
  24. Bahar AY. The frequency of founder mutations in the BRCA1, BRCA2 and APC genes in Australian Ashkenazi Jews: implications for Ashkenazi Jews: implications for the generality of U.S. population data. Cancer. 2001;92:440–5. https://doi.org/10.1002/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O

Most read articles by the same author(s)